Alterity Therapeutics Ltd. reported positive top-line phase II results for lead candidate ATH-434 for treating multiple system atrophy, a rare neurological disorder similar to Parkinson's disease.

Maxim analyst Jason McCarthy raised the firm’s price target on Alterity Therapeutics (ATHE) to $12 from $8 and keeps a Buy rating on the shares ...

Alterity Therapeutics shares are moving higher on Thursday after the company reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy.

Shares of Alterity Therapeutics soared 108% premarket Thursday, surging toward levels last seen in September 2022, with trading volume nearly 75 times the daily average. The clinical-stage biotech ...

Alterity Therapeutics (ATHE) stock jumps as its lead asset, ATH434, shows promise in slowing clinical progression in multiple ...

As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 ...

Alterity Therapeutics (ASX: ATH) has announced positive topline results from a Phase 2 clinical trial of lead candidate ...

and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will ...

Multiple treatments are often needed. Lymphoma is a blood cancer that affects a type of white blood cell known as a lymphocyte. There are many types and subtypes of lymphoma, some of which are ...

Imaging studies have shown brain and cerebellar atrophy. The mechanisms leading to IVIG-induced BP elevation are unclear. BP changes were typically observed minutes after starting infusions ...

The US Food and Drug Administration (FDA) is adding the risk of anaphylaxis to a new boxed warning of glatiramer acetate, a medicine for multiple sclerosis (MS ... disorder that affects the central ...